Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

PURPOSE: Treatment of severe eosinophilic asthma (SEA) has been revolutionized by the development of monoclonal antibodies targeting underlying immunological pathways of eosinophilic asthma. Two of the most frequently used antibodies in clinical practice are mepolizumab, targeting interleukin (IL) 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Kayser, Moritz Z, Drick, Nora, Milger, Katrin, Fuge, Jan, Kneidinger, Nikolaus, Korn, Stephanie, Buhl, Roland, Behr, Jürgen, Welte, Tobias, Suhling, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285237/
https://www.ncbi.nlm.nih.gov/pubmed/34285513
http://dx.doi.org/10.2147/JAA.S319572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285237/
https://www.ncbi.nlm.nih.gov/pubmed/34285513
http://dx.doi.org/10.2147/JAA.S319572

Ejemplares similares